BioCardia Inc
BCDA1.840USD
-0.290-13.62%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
8.61MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über BioCardia Inc Unternehmen
BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS). Its autologous CardiAMP and allogeneic CardiALLO cell therapies intended for cardiac indications of HFrEF and CMI are enabled by its Helix minimally invasive intramyocardial therapeutic delivery platform.
Unternehmensinformationen
BörsenkürzelBCDA
Name des UnternehmensBioCardia Inc
IPO-datumNov 13, 1996
CEODr. Peter Altman, Ph.D.
Anzahl der mitarbeiter17
WertpapierartOrdinary Share
GeschäftsjahresendeNov 13
Addresse320 Soquel Way
StadtSUNNYVALE
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl94085
Telefon16502260123
Websitehttps://www.biocardia.com/
BörsenkürzelBCDA
IPO-datumNov 13, 1996
CEODr. Peter Altman, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Peter Altman, Ph.D.
Dr. Peter Altman, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
167.70K
+16.78%
Mr. Andrew Scott Blank
Mr. Andrew Scott Blank
Independent Chairman of the Board
Independent Chairman of the Board
144.54K
--
Dr. Simon H. Stertzer, M.D.
Dr. Simon H. Stertzer, M.D.
Independent Director
Independent Director
118.69K
+49.48%
Mr. Jim Allen
Mr. Jim Allen
Independent Director
Independent Director
109.66K
--
Mr. David Mcclung
Mr. David Mcclung
Chief Financial Officer
Chief Financial Officer
47.95K
+11.17%
Dr. Richard M. Krasno, Ph.D.
Dr. Richard M. Krasno, Ph.D.
Independent Director
Independent Director
16.27K
+417.27%
Mr. Bill Facteau
Mr. Bill Facteau
Independent Director
Independent Director
13.12K
--
Mr. Jay M. Moyes, CPA
Mr. Jay M. Moyes, CPA
Independent Director
Independent Director
3.62K
-0.06%
Mr. Edward Gillis
Mr. Edward Gillis
Senior Vice President - Devices
Senior Vice President - Devices
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Peter Altman, Ph.D.
Dr. Peter Altman, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
167.70K
+16.78%
Mr. Andrew Scott Blank
Mr. Andrew Scott Blank
Independent Chairman of the Board
Independent Chairman of the Board
144.54K
--
Dr. Simon H. Stertzer, M.D.
Dr. Simon H. Stertzer, M.D.
Independent Director
Independent Director
118.69K
+49.48%
Mr. Jim Allen
Mr. Jim Allen
Independent Director
Independent Director
109.66K
--
Mr. David Mcclung
Mr. David Mcclung
Chief Financial Officer
Chief Financial Officer
47.95K
+11.17%
Dr. Richard M. Krasno, Ph.D.
Dr. Richard M. Krasno, Ph.D.
Independent Director
Independent Director
16.27K
+417.27%
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, May 10
Aktualisiert: Sat, May 10
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Satterfield (Thomas A Jr)
7.12%
Altman (Peter)
3.08%
Blank (Andrew Scott)
2.65%
Stertzer (Simon H)
2.18%
Allen (Jim L)
2.01%
Other
82.97%
Aktionäre
Aktionäre
Anteil
Satterfield (Thomas A Jr)
7.12%
Altman (Peter)
3.08%
Blank (Andrew Scott)
2.65%
Stertzer (Simon H)
2.18%
Allen (Jim L)
2.01%
Other
82.97%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
18.68%
Investment Advisor
3.17%
Corporation
2.66%
Investment Advisor/Hedge Fund
1.34%
Other
74.16%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
50
1.41M
25.85%
+377.00K
2025Q1
56
1.40M
27.94%
+375.61K
2024Q4
58
1.08M
23.60%
+180.41K
2024Q3
57
740.61K
21.37%
-175.94K
2024Q2
60
625.47K
23.03%
-304.05K
2024Q1
60
735.85K
38.95%
-141.63K
2023Q4
61
789.41K
56.72%
+313.00
2023Q3
59
767.08K
57.64%
+35.10K
2023Q2
59
692.26K
54.51%
+36.66K
2023Q1
55
606.10K
49.67%
-69.96K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Satterfield (Thomas A Jr)
388.15K
7.12%
+286.78K
+282.91%
Dec 31, 2024
Altman (Peter)
167.70K
3.08%
+24.10K
+16.78%
Jun 30, 2025
Blank (Andrew Scott)
144.54K
2.65%
--
--
Apr 23, 2025
Stertzer (Simon H)
118.69K
2.18%
+39.29K
+49.48%
Mar 05, 2025
Allen (Jim L)
109.66K
2.01%
-1.00
-0.00%
Dec 31, 2024
Frost Gamma Investments Trust
85.76K
1.57%
-18.98K
-18.12%
Mar 26, 2024
CM Management, LLC
75.00K
1.38%
+50.00K
+200.00%
Mar 31, 2025
Susquehanna International Group, LLP
59.95K
1.1%
+16.11K
+36.74%
Mar 31, 2025
Stertzer Family Trust
59.20K
1.09%
-2.00
-0.00%
Dec 31, 2024
Mcclung (David)
47.95K
0.88%
+4.82K
+11.17%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
May 21, 2024
Merger
15<1
May 21, 2024
Merger
15<1
May 21, 2024
Merger
15<1
May 21, 2024
Merger
15<1
Datum
Art
Verhältnis
May 21, 2024
Merger
15<1
May 21, 2024
Merger
15<1
May 21, 2024
Merger
15<1
May 21, 2024
Merger
15<1
